feed,title,long_url,short_url
Investors,The 'Worst-Case Scenario' â€” Why Insmed Just Reversed Its 181% Six-Month Sprint,https://www.investors.com/news/technology/insmed-stock-brensocatib-failure-rhinosinusitis/,
